European Commission – AfricaNewsAnalysis

Novartis receives EU approval for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis

03/09/2013 ANA 0

Novartis announced today that the European Commission (EC) has approved the use of Ilaris® (canakinumab) in the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older, who have responded […]

Novartis first in class once-daily dual bronchodilator Ultibro® Breezhaler® (QVA149) gains positive CHMP opinion for the treatment of COPD

26/07/2013 ANA 0

Novartis announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler® (indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent […]

Novartis receives positive CHMP opinion for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis

26/07/2013 ANA 0

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Ilaris® (canakinumab) in the treatment of active […]